{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:33:27Z","timestamp":1792690407999,"version":"4.5.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To comprehensively examine the incidence and mortality of malignant neoplasms of bone and articular cartilage (MNBAC) in China compared with the world, as well as its age-specific patterns and sex disparities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The MNBAC burden in China and the world was systematically assessed from 1990 to 2021 based on the Global Burden of Disease 2021, including incidence and mortality data. The estimated annual percentage change was calculated. The pattern of age and gender distribution was carried out. The future trends of MNBAC incidence and mortality through 2030 were predicted using the Bayesian age-period-cohort model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From 1990 to 2021, China experienced rising trends in both the incidence and mortality of MNBAC, increasing at a much faster pace than the world. Before 2005, crude incidence and mortality rates in China increased but plateaued thereafter. In contrast, age-standardized rates displayed a decreasing trend from 2005 onward. During this period, the world experienced relatively stable incidence and mortality rates. The incidence and mortality rates of MNBAC increase with age. The MNBAC burden is higher in males. The rise in incidence and mortality rate in China was predominantly in the elderly. The burden prediction for MNBAC to 2030 showed that China would experience a more significant drop in incidence and mortality rates for MNBAC, along with a decrease in the incidence and mortality cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>From 1990 to 2021, the MNBAC burden in China remains heavy, with incidence and mortality increasing much faster than in the world. The projection results indicate a promising outlook for the future, which is encouraging news. Men and the elderly should be the key target for the public health policies of MNBAC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1629679","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T04:10:39Z","timestamp":1755749439000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Burden of malignant neoplasm of bone and articular cartilage from 1990 to 2021 and its predictions to 2030 in China compared with world"],"prefix":"10.3389","volume":"15","author":[{"given":"Cheng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZhenDong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YunFeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WeiBin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-015-0607-3","article-title":"Bone cancer incidence by morphological subtype: a global assessment","volume":"26","author":"Valery","year":"2015","journal-title":"Cancer Causes Control"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02045","article-title":"Risk factors for primary bone cancer after childhood cancer: A panCare childhood and adolescent cancer survivor care and follow-up studies nested case-control study","volume":"41","author":"Reulen","year":"2023","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1995","article-title":"Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"32","author":"Strauss","year":"2021","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103685","article-title":"SELNET clinical practice guidelines for bone sarcoma","volume":"174","author":"Blay","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1186\/s12885-023-11232-3","article-title":"Radiotherapy in bone sarcoma: the quest for better treatment option","volume":"23","author":"Locquet","year":"2023","journal-title":"BMC Cancer"},{"key":"B7","article-title":"Bone cancer: diagnosis and treatment principles","volume":"98","author":"Ferguson","year":"2018","journal-title":"Am Fam Physician"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.7150\/thno.72800","article-title":"Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness","volume":"12","author":"Panagi","year":"2022","journal-title":"Theranostics"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2013.11.006","article-title":"Osteosarcoma treatment - where do we stand? A state of the art review","volume":"40","author":"Luetke","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3109\/0284186X.2014.923934","article-title":"Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma","volume":"54","author":"Berner","year":"2015","journal-title":"Acta Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-019-02683-w","article-title":"What\u2019s new in bone forming tumours of the skeleton","volume":"476","author":"Franceschini","year":"2020","journal-title":"Virchows Arch"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1126736","article-title":"Quantitative proteomic studies addressing unmet clinical needs in sarcoma","volume":"13","author":"Connolly","year":"2023","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1302\/0301-620X.105B10.BJJ-2023-0443.R1","article-title":"The british orthopaedic oncology management (BOOM) audit","author":"Archer","year":"2023","journal-title":"Bone Joint J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2024.117212","article-title":"Global, regional, and national burden and trends analysis of Malignant neoplasm of bone and articular cartilage from 1990 to 2021: A systematic analysis for the Global Burden of Disease Study 2021","volume":"188","author":"Lai","year":"2024","journal-title":"Bone"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2014-0432-OA","article-title":"Primary Bone Tumors: Epidemiologic Comparison of 9200 Patients Treated at Beijing Ji Shui Tan Hospital, Beijing, China, With 10\u2013165 Patients at Mayo Clinic, Rochester, Minnesota","volume":"139","author":"Niu","year":"2015","journal-title":"Arch\u00a0Pathol Lab Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002547","article-title":"Primary Malignant bone tumors incidence, mortality, and trends in China from 2000 to 2015","volume":"136","author":"Xi","year":"2023","journal-title":"Chin Med J (Engl)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)00367-2","article-title":"Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)00757-8","article-title":"Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)00933-4","article-title":"Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1023\/a:1008953201688","article-title":"Partitioning linear trends in age-adjusted rates","volume":"11","author":"Hankey","year":"2000","journal-title":"Cancer Causes Control"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/bimj.201500263","article-title":"Projecting the future burden of cancer: Bayesian age-period-cohort analysis with integrated nested Laplace approximations","volume":"59","author":"Riebler","year":"2017","journal-title":"Biom J"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5582\/bst.2023.01013","article-title":"The initiation, exploration, and development of hospital-based health technology assessment in China: 2005 \u2013 2022","volume":"17","author":"Tang","year":"2023","journal-title":"Biosci Trends"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/1475-9276-12-40","article-title":"Changes in health expenditures in China in 2000s: has the health system reform improved affordability","volume":"12","author":"Long","year":"2013","journal-title":"Int J Equity Health"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S106258","article-title":"Chinese health care system and clinical epidemiology","volume":"9","author":"Sun","year":"2017","journal-title":"Clin Epidemiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/hpm.2259","article-title":"The impact of expanded health system reform on governmental contributions and individual copayments in the new Chinese rural cooperative medical system","volume":"31","author":"Dong","year":"2016","journal-title":"Int J Health Plann Manage"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(18)30127-X","article-title":"Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries","volume":"6","author":"Zeng","year":"2018","journal-title":"Lancet Glob Health"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2016.0047","article-title":"Epidemic trend, screening, and early detection and treatment of cancer in Chinese population","volume":"14","author":"Zou","year":"2017","journal-title":"Cancer Biol Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2024.100607","article-title":"Trends in primary Malignant bone cancer incidence and mortality in the United States, 2000-2017: A population-based study","volume":"46","author":"Yang","year":"2024","journal-title":"J Bone Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-3697-3","article-title":"Incidence patterns of primary bone cancer in Taiwan (2003-2010): a population-based study","volume":"21","author":"Hung","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"B30","article-title":"Endogenous gonadal hormone exposure and bone sarcoma risk","volume":"11","author":"Cooley","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/oxfordjournals.aje.a116773","article-title":"Sex differences in the risks of hormone-dependent cancers","volume":"138","author":"Dos Santos Silva","year":"1993","journal-title":"Am J Epidemiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1210\/endo.130.5.1572285","article-title":"Estrogens modulate the responsiveness of osteoblast-like cells (ROS 17\/2.8) stably transfected with estrogen receptor","volume":"130","author":"Migliaccio","year":"1992","journal-title":"Endocrinology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-11-0136","article-title":"Age-period-cohort analysis of primary bone cancer incidence rates in the United States (1976-2005)","volume":"20","author":"Anfinsen","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24121","article-title":"Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program","volume":"115","author":"Mirabello","year":"2009","journal-title":"Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28685","article-title":"Young and uninsured: Insurance patterns of recently diagnosed adolescent and young adult cancer survivors in the AYA HOPE study","volume":"120","author":"Parsons","year":"2014","journal-title":"Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.2555","article-title":"Cancer-specific outcomes among young adults without health insurance","volume":"32","author":"Aizer","year":"2014","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-11494-4","article-title":"Non-private health insurance predicts advanced stage at presentation and amputation in lower extremity high grade bone sarcoma: A national cancer database study: amputation predicts survival: an effect most pronounced in pediatric and AYA age group","volume":"29","author":"Jawad","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1302\/2046-3758.115.BJR-2021-0258.R2","article-title":"Impact of racial disparities and insurance status in patients with bone sarcomas in the USA: a population-based cohort study","volume":"11","author":"Hu","year":"2022","journal-title":"Bone Joint Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1629679\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T04:10:41Z","timestamp":1755749441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1629679\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":38,"alternative-id":["10.3389\/fonc.2025.1629679"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1629679","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"article-number":"1629679"}}